Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | EOS-448 |
| Synonyms | |
| Therapy Description |
EOS-448 is a monoclonal antibody that binds to T cell Immunoreceptor with Ig and ITIM domains (TIGIT) and inhibits ligand interaction, potentially leading to increased antitumor immune response (Cancer Res 2020;80(16 Suppl):Abstract nr 3161; Cancer Res 2021;81(13_Suppl):Abstract nr CT118). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| EOS-448 | EOS 448|EOS448|EOS884448|GSK4428859A|Belrestotug | TIGIT Antibody 20 | EOS-448 is a monoclonal antibody that binds to T cell Immunoreceptor with Ig and ITIM domains (TIGIT) and inhibits ligand interaction, potentially leading to increased antitumor immune response (Cancer Res 2020;80(16 Suppl):Abstract nr 3161; Cancer Res 2021;81(13_Suppl):Abstract nr CT118). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05289492 | Phase Ib/II | EOS-448 EOS-448 + Iberdomide Dexamethasone + EOS-448 + Iberdomide | Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma | Terminated | USA | FRA | ESP | BEL | 0 |